A phase 1 trial of a newly developed BCMA-specific CAR-NK 92 cell product has enrolled 20 R/R MM patients aged between 18 and 80 years old in China in May 2019 (NCT03940833). Here, TNFRSF17 is linked to Miyoshi myopathy.